181 related articles for article (PubMed ID: 26932305)
1. Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects.
Mita S; Chitnis SD; Kulmatycki K; Salunke A; He YL; Zhou W; Suzuki H
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):305-14. PubMed ID: 26932305
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
[TBL] [Abstract][Full Text] [Related]
3. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
He YL; Flannery B; Campestrini J; Leon S; Zinny MA; Ligueros-Saylan M; Jarugula V
Curr Med Res Opin; 2008 Jun; 24(6):1703-9. PubMed ID: 18471347
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
6. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
7. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
8. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP
Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864
[TBL] [Abstract][Full Text] [Related]
10. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
[TBL] [Abstract][Full Text] [Related]
11. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
de Bruin TW; Reele S; Hamer-Maansson JE; Parikh S; Tang W
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):118-30. PubMed ID: 27138025
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries.
Chitnis SD; Han Y; Yamaguchi M; Mita S; Zhao R; Sunkara G; Kulmatycki K
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):40-51. PubMed ID: 27119577
[TBL] [Abstract][Full Text] [Related]
15. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
17. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects.
Rojas C; Link J; Meinicke T; Macha S
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):282-92. PubMed ID: 26932302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]